Advertisement
Advertisement
U.S. markets open in 14 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Nexstim Plc (NXTMH.HE)

Helsinki - Helsinki Real Time Price. Currency in EUR
4.1700-0.0250 (-0.60%)
As of 04:16PM EET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.1950
Open4.1600
Bid4.1700 x N/A
Ask4.2000 x N/A
Day's Range4.1600 - 4.3600
52 Week Range3.6200 - 5.9000
Volume1,138
Avg. Volume3,512
Market Cap28.002M
Beta (5Y Monthly)1.78
PE Ratio (TTM)9.07
EPS (TTM)0.4600
Earnings DateAug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NXTMH.HE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute

      Press release, Helsinki, 25 October 2022 at 9 AM (EEST) Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBT® system order from Alamo Neurosurgical Institute (ANI) in San Antonio, Texas. Nexstim NBT® systems uses the unique SmartFocus® TMS technology that enables accurate stimulation of the targeted area in the brain. NBT® system is FDA cleared for marketing and commercial distri

    • GlobeNewswire

      Nexstim Plc Business and Clinical Update Q3 2022

      Press release, Helsinki, 20 October 2022 at 9 AM (EEST) Nexstim Plc Business and Clinical Update Q3 2022 Nexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) announces the key highlights of the Company’s business and clinical operations during Q3 2022. CEO Mikko Karvinen’s Business and Clinical Update After the first positive operating result in the history of the Company in H1 2022, our business has continued to show positive progress during the third quarter of 2022. In line with our ma

    • GlobeNewswire

      Nexstim Plc: Share subscriptions based on stock options 2020A

      Company Announcement, Helsinki, 17 October 2022 at 2 PM (EEST) Nexstim Plc: Share subscriptions based on stock options 2020A Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that between 1 July and 30 September 2022, a total of 21,264 Nexstim Plc’s new shares has been subscribed for with the company's stock options 2020A. For subscriptions made with the stock options 2020A, the entire subscription price of EUR 42,528.00 will be entered in the reserve for invested unrestricte

    Advertisement
    Advertisement